T he avascularity of the cornea is actively maintained in healthy conditions and is necessary to preserve cornea transparency and optimal visual acuity. 1 This ''angiogenic privilege'' relies on the production of antilymph/angiogenic factors such as soluble forms of vascular endothelial growth factor receptor (sVEGFR-1, sVEGFR-2), [2] [3] [4] thrombospondins, 5 angiostatin, endostatin, and pigmented epithelium derived factor, 6 counterbalancing the basal expression of prolymph/ angiogenic factors (e.g., VEGF-A). 1 The avascular cornea can secondarily be invaded by blood vessels (hemangiogenesis) and/or lymphatic vessels (lymphangiogenesis) under severe inflammation. Thus, such a corneal neovascularization (NV) can occur in several pathologic conditions such as hypoxia, infections (e.g., Herpes Simplex Virus, Chlamydia trachomatis), trauma, or keratoplasty, leading to reduced visual acuity. 7 NV, in particular lymphangiogenesis, is also the major factor leading to cornea graft rejection occurring after keratoplasty. 8 The VEGF family members are generally considered as the main regulators of lymph/angiogenesis through the binding to their receptors, the VEGFRs. Among them, VEGF-A enhances hemangiogenesis through VEGFR-2 binding, expressed by blood endothelial cells. VEGF-C and -D are the main prolymphangiogenic factors that act through the activation of VEGFR-3 expressed on lymphatic endothelial cells (LECs). However, LECs also express VEGFR-2 and processed forms of VEGF-C and VEGF-D are also able to bind VEGFR-2, demonstrating interconnections between the two pathways. 9 VEGF-A-mediated corneal NV has been attributed to the stimulation of both hemangiogenesis and lymphangiogenesis, 7,10 directly 11 or indirectly by recruiting inflammatory cells able to deliver VEGF-C and -D. 12 Strategies aiming at blocking VEGF pathway have been developed to inhibit lymph/angiogenesis, and notably consist of anti-VEGF-A antibodies and aptamers (bevacizumab, ranibizumab, pegaptanib) or small molecules designed to inhibit the tyrosine kinase activity of VEGFRs (sunitinib, sorafenib, vatalanib, etc.). Although bevacizumab was approved by Food and Drug Administration (FDA) for cancer and AMD treatment, 13 and several molecules including anti-VEGF antibodies and tyrosine kinase inhibitors have been demonstrated to efficiently inhibit corneal NV in mice models, [14] [15] [16] no treatment specifically targeting lymph/angiogenesis is available to treat corneal NV. 7 Corneal NV is currently treated with corticosteroids, which control inflammatory reaction and display antilymph/angiogenic properties, but their effects are limited and are associated to adverse effects. 7, 17 In the present work, we evaluated the impact of sunitinib on corneal NV. Sunitinib is a multi-target tyrosine kinase inhibitor able to inhibit VEGFRs, platelet-derived growth factor receptor (PDGFR), c-kit and ret, and has already been approved by FDA for the treatment of metastasic renal cell carcinomas and gastro intestinal stromal tumors that are resistant to imatinib. 18 Although antiangiogenic effects of sunitinib through VEGFR-2 inhibition is well recognized, and has been shown in rabbit corneas, 19 its effect on lymphangiogenesis remains unclear. Kodera and colleagues recently demonstrated sunitinib-inhibited lymphangiogenesis in a murine model of breast cancer through VEGFR-3 inhibition. 20 However, whether sunitinib is or is not a potent inhibitor of corneal lymphangiogenesis is still unknown. We demonstrate here that sunitinib exerts in vivo earlier and stronger inhibitory effects on corneal lymphangiogenesis than on hemangiogenesis. These inhibitory effects are associated with reduced F4/80þ cell recruitment. In vitro studies underscore an indirect effect on lymphangiogenesis through the interference with lymphangiogenic factors released by macrophages.
MATERIALS AND METHODS

Mice
Six-week-old male C57BL/6 mice purchased from Janvier (Saint Berthevin, France) were used throughout this study. The animals were maintained with a 12 hour light-dark cycle and had free access to food and water. Animal experiments were performed in compliance with the Animal Ethical Committee of the University of Liège (Liège, Belgium) and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Sunitinib
Sunitinib malate (SU-11248) was purchased from LC Laboratories (Woburn, MA). For in vivo assays, sunitinib was solubilized in 0.5% carboxymethylcellulose and 40 mg/kg were daily administered by oral gavage. Control mice received vehicle. For in vitro assays, sunitinib was solubilized in dimethyl sulfoxide (DMSO) and used at 20 nM in culture medium containing 0.1% DMSO.
Corneal Neovascularization Assay and Immunostainings
Corneal NV was induced by thermal cauterization as previously described. [21] [22] [23] After anesthetizing the mouse with intraperitoneal injection of ketamine hydrochloride (100 mg/kg body weight) and xylazine (10 mg/kg body weight), the anesthetized central cornea (Unicaïne 0.4%; Thea Pharma, Wetteren, Belgium) was thermally cauterized using an ophthalmic cautery (Optemp II V; Alcon Surgical, Fort Worth, TX). Mice were time course sacrificed and eyes were removed and dissected. Whole-mounted corneas were fixed in 70% ethanol for 1 hour at room temperature and blocked in 3% BSA-3% Gloria milk (Nestlé, Brussels, Belgium) for 1 hour.
For double lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) and CD31 immunostainings, corneas were incubated overnight with polyclonal goat antimouse LYVE-1 (1/200; R&D Systems, Abingdon, UK) and rat antimouse CD31 (1/200; BD Biosciences Pharmingen, San Jose, CA). Then incubations with Alexa Fluor 488-coupled rabbit antigoat antibody (1/200; Molecular Probes, Merelbeke, Belgium) and Alexa Fluor 546-coupled goat antirat (1/200; Molecular Probes) were performed for 2 hours. For double LYVE-1-CD11b or F4/80 immunostainings, corneas were incubated overnight with polyclonal goat antimouse LYVE-1 and biotincoupled rat antimouse CD11b (1/250; BD Biosciences) or rat antimouse F4/80 (1/100; Abcam, Cambridge, UK). Alexa Fluor 488-coupled rabbit antigoat antibody (1/200; Molecular Probes) and biotin-coupled rabbit antirat immunoglobulin (1/ 400; Dako, Glostrup, Denmark) were added for 2 hours, followed by 2 hours incubation with Alexa Fluor 555-coupled streptavidin (1/500; Molecular Probes).
Corneas flat-mounted on a microscope slide with Vectashield mounting medium (Vector Laboratories, Burlingame, CA) were examined with a fluorescent microscope (AH3-RFCA; Olympus, Hamburg, Germany). Pictures were taken at 340 magnification and assembled to reconstitute the whole cornea picture with Microsoft Image Composite Editor (Microsoft Corporation, Santa Rosa, CA).
Computerized Methods of Quantification
The previously described computerized quantification method of lymphatic network developing in the cornea was extended to blood vessels. 21 Image processing algorithms were first developed in order to extract blood and lymphatic vessels from the background. This resulted in two independent binary images, in which lymphatic and blood vessels were represented by white pixels (pixels value equal to 1) on a black background (pixels value equal to 0). After binarization, the following automatic measurements were performed: (1) area density defined as the surface covered by vessels reported to total cornea area; (2) end point density defined as the number of vessel extremities per corneal area unit (this parameter indicates the increase/decrease of sprout tips); (3) branching density, defined as the number of vessel branchings per corneal area unit, which indicates the structure degree of complexity; (4) length density, which represents the cumulative length of vessels; (5) maximal length of vessels, which indicates the largest migration distance; and (6) spatial distribution of vessels in relation to the limbal vessel. This distribution gives local information about the number of vessels at each given position in relation to the limbal vessel.
For inflammatory cell quantification (red labeling), the contrast was first enhanced on original red(R)-green(G)-blue(B) color image by combining color components as 2R-G-B images. Heterogeneous illumination was further corrected using a morphological tool (top-hat transformation). 24 Finally, an automatic threshold maximizing the global average contrast across the picture 25 was applied to obtain a binary image with intensity 1 and 0, respectively for inflammatory cells and background. A 0.8-mm thick ring, comprised between the edge of the limbus and the center of the cornea, was arbitrary defined to eliminate unspecific staining present in the center of the cornea and resulting from cauterization. Cell density was calculated as the ratio of pixels belonging to inflammatory cells and the total ring area.
Image processing and measurements were performed using Aphelion 3.2 software (Adcis, Saint-Contest, France) and image analysis toolbox of Matlab 7.9 software (The Mathworks, Inc., Natick, MA).
Macrophage Culture
Peritoneal lavage was performed to isolate primary macrophages from C57BL/6 mice intraperitoneally injected with 4% thioglycollate (T-9032; Sigma-Aldrich, St. Louis, MO) 5 days earlier. Cells were cultured in serum-free RPMI-1640 (Lonza, Braine-l'Alleud, Belgium) for 1 hour at 378C. Non adherent cells were removed by 5 PBS washes. 26 Adherent cells were cultured for 24 hours in serum-free RPMI-1640 before collecting conditioned medium. More than 80% macrophages were identified on cytospins.
Aortic (ARA) and Lymphatic Ring Assays (LRA)
Three-dimensional (3D) aortic or lymphatic ring cultures were performed as described previously. [27] [28] [29] Briefly, aorta dissected from Wistar rats or thoracic duct dissected from C57BL/6 mice were cut into small fragments. The explants were embedded in interstitial type I collagen gel (1.5 mg/mL; Serva, Heidelberg, Germany) and cultured in MCDB131 (Invitrogen, Merelbeke, Belgium). For lymphatic ring assay, medium was supplemented with 2% Ultroser G (BioSepra, Cergy Saint Christophe, France) and explants were cultured under hypoxic conditions (5% O 2 , 5% CO 2 , and 90% N 2 ). In some conditions, 20 nM sunitinib (LC Laboratories, Woburn, MA) or 10% macrophage conditioned medium was added to culture medium. VEGF-A (20 ng/mL; Peprotech, London, UK) was used as positive control in the aortic ring assays. Pictures were taken at the indicated times (6-13 days) and computerized quantifications were performed on binary images as described previously. 29, 30 Briefly, a grid comprised of concentric rings was generated by successive increments at fixed intervals of explant boundary. Then, the number of microvessel grid intersections was counted and plotted versus the distance from the ring to determine microvessel distribution. At least five images per experimental condition were used.
Reverse Transcription-Polymerase Chain Reaction
Frozen corneas were pulverized (MagNA Lyser; Roche, Indianapolis, IN) and total RNA was extracted with a kit (RNeasy; Qiagen, Hilden, Germany) according to the manufacturer's protocol. Cultured cells were washed with cold PBS and total RNA was extracted with a kit (Roche, Indianapolis, IN) according to the manufacturer's protocol. VEGF-A, VEGF-C, VEGF-D, placental growth factor (PlGF), sVEGFR-1, sVEGFR-2, and glyceraldehyde-3-phosphate deshydrogenase (GAPDH) mRNA were amplified with a 10-ng aliquot of total RNA using an amplification kit (GeneAmp Thermostable rTth Reverse Transcriptase RNA PCR Kit; Roche, Branchburg, Germany). Reverse transcription was performed at 708C for 15 minutes followed by RNA-DNA heteroduplexe denaturation at 948C. Amplification started by a 20 second cycle at 948C, 20 seconds at hybridation temperature, and finally 20 seconds at 728C. RT-PCR products were resolved in 10% acrylamide gels after staining with Gel Star (Cambrex, East Rutherford, NJ). The primer sequences, hybridation temperatures, number of cycles, and the length of the RT-PCR products are described in the Table. Endothelial Cell Culture and Western Blotting LECs purchased from Lonza (HMVEC-dLy; Braine-l'Alleud, Belgium) were cultured in endothelial growth medium microvascular (EGM2-MV) medium (Lonza) supplemented with 5% fetal calf serum (FCS) and L-glutamine (Invitrogen) until confluence was reached. Cells were then rinsed with PBS and placed for 24 hours in endothelial basal medium (EBM2) serum-free medium (Lonza). Medium was then replaced by EBM2 containing 20 nM sunitinib or 0.1% DMSO for 2 hours, and cells were stimulated with 10% macrophage conditioned medium for 10 minutes. In some samples, macrophage conditioned medium was preincubated for 1 hour with 500 ng/mL sVEGFR-1 or sVEGFR-3 (R&D Systems) to trap VEGF-A or VEGF-C and -D, respectively. Cells were rinsed with ice cold PBS and lysed with radioimmunoprecipitation assay (RIPA) buffer containing phosphatase and protease inhibitors (Roche, Vilvoorde, Belgium). Samples were dissolved in SDS buffer and migrated on 12% SDS-PAGE gel before being transferred onto a polyvinyl difluoride (PVDF) membrane. After 1 hour blocking in 1% casein, phosphorylated, and total proteins were detected by 48C overnight incubation with the respective antibodies, followed by 1 hour room temperature incubation in HRPcoupled secondary antibody (Cell Signaling, San Diego, CA) and ECL revelation in LAS4000 imager (Fujifilm, Tokyo, Japan). The following antibodies were used: rabbit monoclonal antiphospho-Akt, Akt, phospho-ERK1/2, ERK1/2, phospho-VEGFR-2 and VEGFR-2 (Cell Signaling).
Proliferation and Tubulogenesis Assay
For proliferation assay, 4 3 10 3 LECs (HMVEC-dLy; Lonza) were seeded in wells of 96-well plate and were grown overnight in EGM2-MV medium (Lonza). Medium was then replaced by serum-free EBM2 medium (Lonza) for 2 hours and cells were stimulated with 50% macrophage conditioned medium for 48 hours containing 20 nM sunitinib or not. In some samples, macrophage conditioned medium was preincubated for 1 hour with 1 lg/mL sVEGFR-1 or sVEGFR-3 (R&D Systems) to trap VEGF-A or VEGF-C and -D, respectively. Cell proliferation was then assessed using WST-1 proliferation kit (Roche, Indianapolis, IN) according to the manufacturer's protocol. For tubulogenesis assay, 3 3 10 5 LECs were seeded on a type I collagen layer (1 mg/ml, Collagen R; Serva Electrophoresis, Heidelberg, Germany) in a 12-well plate. Cells were grown for 24 hours in EGM2-MV medium. Medium was then removed and a second layer of collagen was added over the cells. Finally, collagen-embedded LECs were incubated in 500 lL of serumfree EBM2 medium containing or not 50% macrophage conditioned medium and/or 20 nM sunitinib. After 6 hours, five pictures per well were captured with a phase-contrast microscope (Axiovert 25; Carl Zeiss Microscopy, Zaventem, Belgium) coupled to an Axiocam color digital camera (Carl Zeiss) and tube length was measured.
RESULTS
Time Course Corneal Lymph/Angiogenesis
Corneal NV was induced in C57BL/6 mice by thermal cauterization. Mice were time course sacrificed to concomitantly evaluate the progression of blood and lymphatic networks developing in the cornea by double LYVE-1-CD31 immunostaining on whole-mounts (Fig. 1A) . In healthy corneas (Day 0), blood and lymphatic vessels were restricted to the limbus but some lymphatics extended in the cornea as previously described. 31 Three days after cauterization, significant hemangiogenesis was observed that persisted until day 21. This was followed by a strong blood vessel regression observed after 40 days. The lymphangiogenic process took place more slowly with some short sproutings appearing on lymphatic vessels at day 3 (Fig. 1A) . Lymphatic vessels strongly expanded between days 7 and 21. Lymphatic vessel regression occurred in a lesser extent than the blood vessel ones. A significant number of lymphatic vessels were still observed in the center of corneas after 40 days (Fig. 1A) . These vascular changes were quantified through an original computerized method (Fig. 1B) , and objectivized through four parameters: area density, length density, branching density, and end point (sprout tip) density. Regarding hemangiogenesis, all these parameters evidenced a linear and rapid blood vessel growth that occurred until day 21 and was followed by a strong regression leading to a bell shape curve. A latency phase of 5 to 7 days was observed for lymphangiogenesis, followed by a rapid growth of lymphatic vessels, and finally, a regression phase (Figs. 1C-F) . The number of lymphatic vessels being far inferior to blood vessel ones, lymphatic area density and length density were much lower than blood vessel densities. Beside area and length densities that provide an overall information on blood and lymphatic vessel growth (Figs. 1C, 1D ), branching and end point densities give quantitative information about the complexity of these vascular networks (Figs. 1E, 1F ). This quantification underlines that blood vessels presented much more branchings and end points than lymphatics reflecting a much more complex and ramified plexus.
Sunitinib Inhibits Both Corneal Hemangiogenesis and Lymphangiogenesis
Corneal NV was induced in mice administered with 40 mg/kg sunitinib by daily oral gavage. Mice were sacrificed 6, 11, or 17 days after cauterization and corneas were immunostained for LYVE-1 and CD31. At early time points (days 6 and 11), sunitinib did not inhibit the sprouting of blood vessels and similar number of end points and branchings were observed in the two experimental groups (Figs. 2A-D) . Nevertheless, although similar blood vessel density was observed near the limbus, the maximal distance of cell migration (Lmax) was significantly reduced at day 11 upon sunitinib treatment (Lmax ¼ 0.82 6 0.05 in controls versus 0.62 6 0.04 in sunitinib treated P ¼ 0.0012) (Fig. 2E) . This indicates that sunitinib inhibited blood vessel elongation at early time points. At day 17, all parameters measured were 1.8-fold decreased in sunitinib-treated mice compared with controls (P < 0.001) ( Figs. 2A-E) . Notably, the density of vessels closed to the limbus (distance below 0.4 mm) was drastically decreased suggesting a regression of neoformed blood vessels (Fig. 2F) . Therefore, the computer-assisted quantification reveals that sunitinib did not influence the sprouting of new vessels from the limbal vessels, but mainly impaired vessel elongation and induced neoformed vessel regression. These observations are consistent with the capacity of sunitinib to block VEGF and PDGF receptors. Regarding lymphatic vasculature, all parameters measured were reduced from day 6 to day 17 (P < 0.001) (Figs. 2G-K) , suggesting a rapid inhibition of both lymphatic vessel sprouting and elongation. This is supported, at least, by the decreased vessel density detected upon sunitinib treatment, at a distance lower than 0.4 mm from the limbus.
Sunitinib Inhibits Inflammatory Cell Recruitment in the Cornea
We then evaluated the recruitment of inflammatory cells after cornea cauterization in mice treated or not with sunitinib through immunostaining directed against CD11b, which is a general marker of inflammatory cells, or F4/80, which is more specific of monocytic cells such as macrophages. Inflammatory cells, especially macrophages, are indeed known to play an important role in cornea NV, being at least a source of prolymph/angiogenic factors. 12 Through a preliminar time course analysis of inflammatory cell recruitment in cauterized cornea, we previously observed an early CD11bþ cell infiltration peaking at 1 and 2 days post cauterization. F4/80þ cells appeared later, from day 3 to day 14 post cauterization. Double LYVE-1-CD11b and LYVE-1-F4/80 whole-mount immunostainings were conducted at different time points (Fig.  3B) . Immunostaining quantification was performed after image binarization (Fig. 3A) . Strong CD11bþ cell infiltration was observed in both experimental groups and quantification did not revealed any difference between mice treated with sunitinib and controls, 2 days or 7 days after cauterization (Figs. 3B, 3C ). An important recruitment of F4/80þ cells was observed in control corneas after 3, 7, and 14 days. Notably, a reduction of F4/80þ cell infiltration was already observed at day 3 and persisted until day 14 in corneas from sunitinibtreated mice (P < 0.001 for day 3, P < 0.05 for day 7, P < 0.01 for day 14) (Fig. 3C) .
Since inflammatory cells are major producers of prolymph/ angiogenic molecules, notably VEGF-A, -C, and -D, and PlGF, we analyzed the expression levels of these factors by RT-PCR analysis of mRNA extracted from corneas treated or not with sunitinib, as well as the expression level of sVEGFR-1 and sVEGFR-2 reported as a regulator of angiogenesis and lymphangiogenesis, respectively. 2, 3 At day 7, VEGF-A mRNA levels were reduced 2-fold in sunitinib treated corneas after cauterization (P < 0.01) (Supplementary Data S1A, S1B). VEGF-C expression was reduced by 35% at day 21, but not modulated at earlier time point (P < 0.01) (Supplementary Data S1C, S1D). VEGF-D and PlGF mRNA levels were weak and no difference was observed between the experimental groups (Supplementary Data S1A, S1B). Identically, sVEGFR-1 and sVEGFR-2 expressions were not affected by sunitinib treatment (Supplementary Data S1A, S1B). 
Sunitinib Inhibits In Vitro Hemangiogenesis but Not Lymphangiogenesis
We next performed in vitro aortic and lymphatic ring assays to evaluate whether sunitinib could directly inhibit angiogenesis and lymphangiogenesis (Fig. 4) . By adding increasing concentrations of sunitinib (from 1-1000 nM) in the culture medium of the aortic rings, we evidenced a strong inhibitory effect on angiogenesis from 10 nM doses (Fig. 4D) . Upon VEGF-A stimulation of the aortic ring, the angiogenic response was enhanced (Figs. 4A [left and middle panels], 4B, 4D) . This VEGF-A-mediated angiogenic activity was drastically reduced by the addition of 20 nM sunitinib (Figs. 4A, 4B, 4D) . In other experiments, aortic rings were first cultured with sunitinib during 6 days leading to a strong inhibition of endothelial cell spreading out. When the culture medium was replaced by sunitinib-free medium, blood capillary growth was rescued demonstrating that the antiangiogenic effects of sunitinib does not rely on a toxic effect on endothelial cells (data not shown). Surprisingly, in the lymphatic ring assay, sunitinib failed to affect lymphangiogenesis, at concentrations ranging from 1 to 1000 nM (Figs. 4A [right panels], 4C, 4E ). These data suggest that sunitinib does not exert a direct inhibitory effect on LECs. It is worth mentioning that the impact of sunitinib in the lymphatic ring assay has been tested in the presence of 2% Ultroser leading to an optimal lymphangiogenic reaction. Therefore, the failure of sunitinib to block LEC sprouting cannot be ascribed to too low proliferation rate. FIGURE 2. Sunitinib administration inhibits corneal neovascularization. Computer-assisted quantification of blood (A-F) and lymphatic (G-K) vascular networks developing in the cornea after cauterization, in mice treated with sunitinib (black columns) or not (white columns). Vessel area (A, G), branching (B, H), end point (C, I), and total length (D, J) densities, as well as maximal length of vessels (Lmax) (E), and vessel distributions (F, K) were evaluated. *P < 0.05; **P < 0.01; ***P < 0.001. the blood (black curve) and lymphatic (grey curve) vasculatures were normalized to the total area of the cornea (density) and include: area covered by neoformed vessels (area density, [ 
Sunitinib Inhibits Macrophage-Induced Lymph/ Angiogenesis
To next evaluate the role of macrophages on lymph/ angiogenesis in vitro, macrophages isolated from the peritoneal cavity were treated overnight with 20 nM sunitinib or 0.1% DMSO. RT-PCR analyses revealed high expression levels of VEGF-A, VEGF-C, and VEGF-D without any modulation by sunitinib treatment (data not shown). Media conditioned by macrophages were then used in in vitro experiments of aortic and lymphatic ring assays (Fig. 5) . The growth of aortic explants cultured in the presence of macrophage conditioned medium was increased as compared with controls and nearly similar to that of explants exposed to 10 ng/mL recombinant VEGF-A (Figs. 5A, 5B ). Ring treatment with 20 nM sunitinib induced a significant reduction of capillary outgrowth compared with control rings (Figs. 5A, 5B) .
In an identical manner, macrophage conditioned medium strongly stimulated lymphatic ring growth (Figs. 5C, 5D ). While sunitinib did not reduce the growth of nonstimulated lymphatic rings (Figs. 4A, 4C, 4E) , a strong inhibition of macrophage-induced lymphangiogenesis was observed (Figs. .3 mm) . #, *P < 0.05; **P < 0.01; ***P < 0.001 (* compares sunitinib-treated conditions with control and # compares VEGF-A 10 ng/mL þ sunitinib condition with VEGF-A 10 ng/mL condition).
significantly reduced LEC proliferation while sVEGFR-3 failed to do it, suggesting that VEGF-A is the major prolymphangiogenic factor secreted in the macrophage conditioned medium (Fig. 6) . Concordantly, medium conditioned by macrophages induced the phosphorylation of VEGFR-2 and two downstream mediators (Akt and ERK1/2) as assessed by Western blot (Supplementary Data S3) . Upon sunitinib treatment, the phosphorylation levels were drastically reduced demonstrating the implication of VEGFR-2 pathway in the observed effects. Moreover, conditioned medium preincubated with sVEGFR-1 induced weaker VEGFR-2 phosphorylation compared with control macrophage conditioned medium. Conversely, preincubation with sVEGFR-3 did not affect the level of phosphorylated proteins (Supplementary Data S3).
DISCUSSION
Our study sheds light on the inhibition of corneal NV through the use of a broad spectrum tyrosine kinase inhibitor. We, here, provide evidence for combined antihemangiogenic and antilymphangiogenic potential of sunitinib, of interest for ocular disorders. Sunitinib induces a biphasic response on corneal NV with a rapid and early inhibition of lymphangiogenesis, followed by a blockade of hemangiogenesis. The lymphangiogenesis inhibitory action relies at least on its capacity to reduce inflammatory cell recruitment and to interfere with their secreted growth factors.
Pérez-Santonja and colleagues previously showed that topical sunitinib and bevacizumab administrations were able to inhibit corneal angiogenesis in a rabbit suture-induced model. 19 However, corneal NV not only relies on hemangiogenesis, but also on lymphangiogenesis, which has been described as playing a major role in cornea graft rejection by providing a route for antigens and antigen presenting cells to regional lymph nodes. 8, 32 Our results provide evidence for a strong lymphangiogenesis inhibitory potential of sunitinib. Notably, this lymphangio-inhibitory action of sunitinib is exerted earlier than its antihemangiogenic effects. Our results are in line with the inhibitory effect of sunitinib on For quantification, grid corresponding to successive increments at fixed intervals of explant boundary was used on binarized images and the number of microvessel grid intersections (N i ) was quantified on binarized images. #, *P < 0.05; ##P < 0.01 (* compares sunitinib-treated condition with control and # compares macrophage conditioned medium þ sunitinib condition with macrophage conditioned medium condition).
lymphangiogenesis observed in vivo in a murine breast cancer model. 20 We also provide evidence that sunitinib, in addition to reducing blood and lymphatic vessel growth, is able to inhibit F4/80þ cell recruitment, but not CD11bþ cell infiltration. Accordingly, other tyrosine kinase inhibitors, such as PTK787/ ZK222584 and ZK261991, have been reported to display similar inhibition of macrophage recruitment in corneal NV model. 16 Reduced F4/80þ cell infiltration could result from the inhibition of VEGF-A/VEGFR-1 pathway. Infiltrating macrophages represent a major source of prolymph/angiogenic factors such as VEGF-A, -C, and -D, leading to an immune amplification. 12 It has been reported that macrophages can also take part in the formation of lymphatic vessels by transdifferentiating into an endothelial phenotype and incorporating into the lymphatic wall. 33, 34 The reduced F4/80þ cell infiltration observed in our experimental model was associated to a reduction of corneal expression of VEGF-A and -C upon sunitinib treatment, although sunitinib treatment did not affect their expression in isolated macrophages. This observation suggests an indirect effect of sunitinib by interfering with F4/ 80þ cell recruitment, thereby reducing the release of prolymphangiogenic factors. In addition to its impact on inflammatory cell recruitment, sunitinib is able to abrogate the effects of factors secreted by macrophages as demonstrated in the in vitro ring assays.
Surprisingly, although we observed a strong inhibition of lymphangiogenesis in vivo upon sunitinib treatment, no inhibitory effect was observed in vitro in the lymphatic ring assay. Notably, upon lymphatic ring stimulation with macrophage conditioned medium, sunitinib reduced LEC outgrowth to a level comparable of control conditions. This indicates that the effect of sunitinib in vivo relies on its capacity to interfere with prolymphangiogenic factors produced by macrophages. This concept is further supported by the capacity of sunitinib to block macrophage-mediated LEC proliferation and tube formation, as well as to inhibit the activation of VEGFR-2 pathway. The blockade of macrophage-mediated mitogenic effect by sVEGFR1 underlines the key contribution of VEGF-A in this process. In sharp contrast, hemangiogenesis was both inhibited in vivo and in vitro in the aortic ring assay, in basal conditions, as well as under VEGF-A or macrophage conditioned medium stimulation. It is worth mentioning that the aortic wall contains macrophages that could contribute to the endogenous release of angiogenic factors leading to an angiogenic response sensitive to sunitinib treatment. 35, 36 Treatments targeting lymph/angiogenesis have largely been developed in the past years and are now available to treat different tumor types and ocular pathologies affecting posterior segment of the eye. 13 However, pathologic corneal NV still lacks specific management, while being major factor of vision impairment and strongly associated with the risk of cornea graft rejection. 7, 37 Angiogenesis and lymphangiogenesis are intricate processes in cornea NV and share common regulatory pathways. 9 We provide data showing strong combined inhibition of corneal angiogenesis and lymphangiogenesis by sunitinib, suggesting a potential interest for corneal NV treatment. Importantly, a transient in vivo administration of sunitinib (during the first 6 days following cornea cauterization) was not sufficient to efficiently repress corneal NV. Similarly, no inhibitory effect of a transient sunitinib treatment was observed in vitro in the aortic ring assay. These data suggest a rapid regrowth of blood vessels after treatment withdrawal. This observation implies a sustained sunitinib exposure to treat ocular disorders. Previous studies demonstrated that corneal NV inhibition through VEGF-A blockade promoted cornea graft survival in murine model. 15, 38 Not only has VEGF-A been implicated in corneal NV, but also PDGF through its action on vessel stabilization, 39 as well as VEGF-C and -D that activate lymphangiogenesis. [40] [41] [42] A combined inhibition of VEGFR-2 and PDGFR in blocking corneal angiogenesis has proven more efficient than single VEGF-A pathway blockade. 43, 44 The use of multi-target tyrosine kinase inhibitors also provides higher survival rate for cornea engraftment. 16 We, herein, provide evidence that the use of a multi-potent tyrosine kinase inhibitor such as sunitinib, both targeting effectors of hemangiogenesis and of lymphangiogenesis, could provide higher efficiency in the treatment of corneal NV.
In conclusion, our study provides evidence for strong antilymph/angiogenic potential of sunitinib in inflammationinduced corneal NV, acting through the inhibition of F4/80þ cell recruitment in inflamed corneas, thereby decreasing the secretion of VEGF-A and -C. The use of such a multi-target tyrosine kinase inhibitor could be considered for treatment in order to prevent cornea vascularization occurring in inflammatory conditions and to increase cornea graft survival in case of keratoplasty.
